BUSINESSSTAT NEWS
STAT+: Argenx to buy Forte Biosciences for $2.2B
Argenx agreed to acquire Forte Biosciences for $2.2 billion in cash, valuing the Dallas-based company at $77 per share, a 41% premium. The deal aims to expand Argenx's immunology pipeline, leveraging its success with the autoimmune drug Vyvgart.
Related Signal
Adjacent reporting
- STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
- STAT+: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
- STAT+: Pharmalittle: We’re reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
- STAT+: Pharmalittle: We’re reading about a $10 billion Vertex deal, the pace of FDA drug approvals, and more